Biohaven Pharma (BHVN) Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. ACN
2. SPCX
3. NVDA
4. MSTR
5. MU
6. DFTX
7. BAUFF
8. ICE
9. KR
10. RGA

Go back to Biohaven Pharma (BHVN) Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300

Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $63 at Jefferies

March 5, 2025 5:21 AM EST

Jefferies analyst Amy Li lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $63.00 (from $64.00) while maintaining a Buy rating.

The analyst comments "BHVN provided program updates during Q4 earnings. Our thoughts - BHV-1300: While we see +'ves in data (~80% median... More

Piper Sandler Reiterates Overweight Rating on Biohaven Pharmaceutical Holding (BHVN)

March 3, 2025 12:35 PM EST

Piper Sandler analyst Christopher J. Raymond reiterated an Overweight rating and $76.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).

The analyst comments "Remain OW rated on BHVN shares following a Q424 update and the announcement of additional P1 MAD data for IgG... More